Douglas J. Saltel
President, Gollip Pharma
Doug joined the Gollip Pharma team after more than 33 years on the innovator/brand side of the pharmaceutical industry.
Most recently, Doug was the Founder, Chairman and CEO of Edgemont Pharmaceuticals LLC. A company focused on the development and commercialization of Psychiatry related products and was ranked #268 in Fortune 500 fastest growing US private companies in 2016.
Prior to Edgemont, Doug, held many senior level roles, including: President and COO of QRxPharma Ltd; Head of the U.S. Neuroscience Business Unit of Novartis – where he led the Unit to more than double its annual sales, exceeding $ 1.1 billion in the year of his departure; and VP Marketing, CNS, Anti-Infectives and Oncology at Parke-Davis US – where his product portfolio experienced a 5 fold increase in sales to reach over $ 2.3 Billion.
Doug is also the co-inventor on several issued product patents in the fields of pain management and anxiety related disorders.